共查询到20条相似文献,搜索用时 78 毫秒
1.
Yo Ueda Hiroyuki Yamashita Yuko Takahashi Hiroshi Kaneko Toshikazu Kano Akio Mimori 《Clinical rheumatology》2014,33(2):281-286
We experienced three patients with refractory or severe hemophagocytic syndrome associated with the activity of systemic lupus erythematosus, so-called acute lupus hemophagocytic syndrome (ALHS). All patients were successfully treated with intermittent intravenous injections of cyclophosphamide (IVCY). In each patient, hemophagocytosis was found during bone marrow examination, and infectious causes of hemophagocytic syndrome were carefully excluded. Patients 1 and 2 were refractory to combination therapy with a high-dose corticosteroid and rituximab or cyclosporine and were successfully treated with additive IVCY. Patient 3 had very severe ALHS that developed after cardiac surgery but was successfully treated with a high-dose corticosteroid and IVCY. We conducted a literature review of adult ALHS and analyzed 54 cases reported from 2006 to 2013. Although the clinical and laboratory features were diverse, fever, bicytopenia or pancytopenia, and hyperferritinemia were almost universal. Including our 3 patients, a total of 16 have reportedly been treated with IVCY-containing regimens, and ALHS was successfully controlled in most of them without switching or adding other therapies. We suggest that combination therapy with IVCY and corticosteroids may be useful to treat severe or refractory ALHS. 相似文献
2.
《Modern rheumatology / the Japan Rheumatism Association》2013,23(5):855-857
AbstractHigh-dose steroids, immunosuppressants such as cyclophosphamide and cyclosporine, and high-dose intravenous immunoglobulin have all been used to control hemophagocytic lymphohistiocytosis (HLH) or autoimmune hemolytic anemia (AIHA) associated with systemic lupus erythematosus (SLE); however, some patients are refractory to treatment. Rituximab has successfully resolved many of the refractory manifestations of SLE. Here, we report a case of HLH and AIHA associated with SLE that was refractory or intolerable to conventional therapy, but was successfully treated with rituximab. 相似文献
3.
Hagiwara K Sawanobori M Nakagawa Y Sato T Akiyama O Takemura T 《Modern rheumatology / the Japan Rheumatism Association》2006,16(3):169-171
A 38-year-old woman with pancytopenia and liver dysfunction was diagnosed with active systemic lupus erythematosus (SLE).
On days 9 and 10 of admission, peripheral blood smears showed macrophages phagocytosing platelets, and reactive hemophagocytic
syndrome (HPS) was diagnosed. Hemophagocytic syndrome was successfully treated with high-dose prednisolone therapy and one
course of methylprednisolone pulse therapy. Detection of hemophagocytosing macrophages in peripheral blood smears would be
a useful and noninvasive method of diagnosing SLE-associated HPS. 相似文献
4.
The acute lupus hemophagocytic syndrome 总被引:14,自引:0,他引:14
OBJECTIVE: To characterize an unusual mode of presentation of systemic lupus erythematosus: acute and severe pancytopenia related to reactive hemophagocytosis. DESIGN: Retrospective case series. SETTING: Two general community hospitals in Hong Kong. PATIENTS: Six patients presenting with a reactive hemophagocytic syndrome, identified over a 3.5 year period, diagnosed with systemic lupus erythematosus according to the criteria of the American Rheumatism Association. RESULTS: In addition to severe pancytopenia and marrow hemophagocytosis, other characteristic features were fever, hypocomplementemia, high antinuclear antibody titer, and cutaneous and visceral vasculitis. There was no evidence of an underlying infection. The pancytopenia responded dramatically to treatment with steroids. CONCLUSION: Recognition of the acute lupus hemophagocytic syndrome and distinction from an infection-associated hemophagocytic syndrome is important because it responds well to steroid therapy. The evaluation of patients presenting with a hemophagocytic syndrome should include serologic tests for systemic lupus erythematosus. 相似文献
5.
T. Bohgaki M. Mukai A. Notoya M. Kondo M. Kohno U. Okushiba 《Modern rheumatology / the Japan Rheumatism Association》2001,11(2):165-167
A 24-year-old woman suffered from blurred vision and periorbital edema with remittent fever. She was diagnosed as having
systemic lupus erythematosus (SLE), complicated with myopia and retinopathy and severe chemosis. Antiphospholipid syndrome
(APS), hemophagocytic syndrome, and liver involvement were also proven. We considered that APS might cause chemosis as a result
of thrombosis-induced perfusion failure in the conjunctiva. In such cases, APS should be considered and anticoagulation therapy
associated with steroid therapy should be initiated. In systemic lupus erythematosus (SLE), chemosis, severe hepatitis, and
hemophagocytic syndrome (HPS) are rare complications. It is well known that many cases of SLE are complicated with antiphospholipid
syndrome (APS), which causes arteriovenous thrombosis. We report a case of SLE with transient myopia and severe chemosis complicated
with severe hepatitis and HPS. As this patient had antiphospholipid antibodies, these ocular complications were considered
to be related to APS.
Received: August 23, 2000 / Accepted: November 24, 2000 相似文献
6.
Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus 总被引:1,自引:0,他引:1
STUDY OBJECTIVE: to determine the efficacy of danazol therapy in patients with systemic lupus erythematosus with severe autoimmune thrombocytopenia refractory to other therapies. DESIGN: noncontrolled clinical trial, with a minimum of 8 weeks of therapy, the maximum determined by clinical response. SETTING: referral-based rheumatology clinic at an army medical center. PATIENTS: sequential sample of six patients with systemic lupus erythematosus with severe autoimmune thrombocytopenia refractory to high-dose glucocorticoids. Four patients also failed splenectomy, or cytotoxic drugs, or both. INTERVENTIONS: danazol, 200 mg four times per day, was added to the previous therapeutic regimen for at least 2 months. MEASUREMENTS AND MAIN RESULTS: all six patients had normal platelet counts within 6 weeks of starting danazol treatment. After resolution of thrombocytopenia for at least 1 month, immunosuppressive medications were tapered; one patient had a relapse. During an average follow-up of 12 months, the danazol dose was lowered in the five remaining patients but could not be discontinued without recurrence of thrombocytopenia. During danazol therapy, platelet-bound IgG antibodies and circulating immune complexes did not decrease significantly. Danazol was well tolerated. CONCLUSIONS: danazol appears to be a useful adjunctive treatment for refractory autoimmune thrombocytopenia associated with systemic lupus erythematosus. 相似文献
7.
Kwon CM Jung YW Yun DY Kim HD Cho HS Hong YH Choi JH Lee CK 《Rheumatology international》2008,28(3):271-273
Hemophagocytic syndrome, cytomegalovirus infection and systemic lupus erythematosus (SLE) would each be critical diseases
separately. Viral infections, autoimmune diseases or malignancies can complicate the Hemophagocytic syndrome. Cytomegalovirus
infection is known to be prevalent in immune compromised hosts, and can exacerbate the symptoms of systemic lupus erythematosus.
A 25-year-old man presented with fever and acute pericarditis with the hemophagocytic syndrome, cytomegalovirus infection
and systemic lupus erythematosus; all developed concurrently at the onset of illness. With treatment, using ganciclovir and
glucocorticoid medication the patient improved. Here we report this rare case and review the medical literature. 相似文献
8.
S. Banno Y. Sugiura T. Yoshinouchi Y. Matsumoto R. Ueda 《Modern rheumatology / the Japan Rheumatism Association》2000,10(4):263-266
A 31-year-old woman who had been administered corticosteroid and immunosuppressive agents for systemic lupus erythematosus
(SLE) without flare-up was diagnosed as having reactive hemophagocytic syndrome (HPS) with severe disseminated intravascular
coagulation. The causative underlying disease was uncertain, but it was not the SLE itself. Her fulminant HPS with increased
serum ferritin and inflammatory cytokines (sIL-2R, TNF-α, IL-6, and IFN-γ) was successfully treated with plasmapheresis and
high-dose γ-globulin therapy.
Received: December 24, 1999 / Accepted: June 28, 2000 相似文献
9.
Mariko Taira Takeshi Matsumura Yoshiko Sumita Mayuko Moriyama Masahiro Kondo Noriyoshi Ishikawa Yasuko Wada Mamiko Nagase Emiko Nishikawa Yukari Tsubata Koji Kishimoto Yohko Murakawa 《Internal medicine (Tokyo, Japan)》2022,61(4):559
Acute fibrinous and organizing pneumonia (AFOP) is rare in patients with systemic lupus erythematosus (SLE). We herein report a case of AFOP with SLE and hemophagocytic syndrome. Early-phase high-resolution computed tomography showed a fine granular lung pattern. A pathological examination revealed AFOP. An immunohistological examination revealed numerous CD163+ and fewer CD68+ macrophages present in the lung tissue and in alveolar spaces as well, including fibrin balls, the interstitium, and bronchial walls. Pneumonia and thrombocytopenia worsened during high-dose steroid therapy, plasma exchange, and intravenous immunoglobulin administration. The addition of intravenous cyclophosphamide successfully ameliorated the symptoms and radiographic lesions. Therefore, this therapy may be useful for treating severe AFOP. 相似文献
10.
《Modern rheumatology / the Japan Rheumatism Association》2013,23(2):308-311
AbstractA 41-year-old woman presented with continuous fever, and her laboratory data suggested the recrudescence of systemic lupus erythematosus. She was treated with 60 mg/day prednisolone. With a dose reduction of prednisolone, high fever and pancytopenia were observed again. A bone marrow biopsy revealed hemophagocytosis. The effects of steroid pulse therapy, high-dose intravenous immunoglobulin, cyclosporine A, and methotrexate were insufficient. However, after four injections of etanercept (25 mg, twice a week) subcutaneously, her symptoms had completely resolved. In such cases, therapy with etanercept may be effective. 相似文献
11.
Kikuchi H Yamamoto T Asako K Takayama M Shirasaki R Ono Y 《Modern rheumatology / the Japan Rheumatism Association》2012,22(2):308-311
A 41-year-old woman presented with continuous fever, and her laboratory data suggested the recrudescence of systemic lupus
erythematosus. She was treated with 60 mg/day prednisolone. With a dose reduction of prednisolone, high fever and pancytopenia
were observed again. A bone marrow biopsy revealed hemophagocytosis. The effects of steroid pulse therapy, high-dose intravenous
immunoglobulin, cyclosporine A, and methotrexate were insufficient. However, after four injections of etanercept (25 mg, twice
a week) subcutaneously, her symptoms had completely resolved. In such cases, therapy with etanercept may be effective. 相似文献
12.
Pulmonary hypertension is a common but underdiagnosed complication of systemic lupus erythematosus, which can be associated with significant morbidity and early mortality. Although often associated with anti-phospholipid antibodies, the etiology remains poorly understood. In case reports and small open trials, the anti-CD20, B-cell targeted therapeutic antibody, rituximab, has been reported to provide benefits for systemic lupus erythematosus patients with glomerulonephritis, anti-phospholipid antibody syndrome, vasculitis, arthritis, and refractory skin disease. However, the outcome of rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus has not been described. We, therefore, present a case of a young systemic lupus erythematosus patient with early onset of pulmonary arterial hypertension during the disease course, refractory to multiple treatment modalities, who had significant improvement with rituximab therapy. 相似文献
13.
Yoshiro Horai Tomoya Miyamura Soichiro Takahama Koshiro Sonomoto Masataka Nakamura Hitoshi Ando Rumi Minami Masahiro Yamamoto Eiichi Suematsu 《Modern rheumatology / the Japan Rheumatism Association》2010,20(2):178-182
We report a 24-year-old male with systemic lupus erythematosus (SLE) who developed influenza virus B-associated hemophagocytic
syndrome and cardiac tamponade. Although the patient’s general condition improved after steroid pulse therapy and pericardiocentesis,
pericardial effusion re-accumulated. Colchicine and aspirin were administered, together with prednisolone, after which no
further relapses occurred. This was a rare case of severe influenza-associated hemophagocytic syndrome and steroid-resistant
pericardial effusion in an SLE patient. 相似文献
14.
《Modern rheumatology / the Japan Rheumatism Association》2013,23(2):178-182
AbstractWe report a 24-year-old male with systemic lupus erythematosus (SLE) who developed influenza virus B-associated hemophagocytic syndrome and cardiac tamponade. Although the patient’s general condition improved after steroid pulse therapy and pericardiocentesis, pericardial effusion re-accumulated. Colchicine and aspirin were administered, together with prednisolone, after which no further relapses occurred. This was a rare case of severe influenza-associated hemophagocytic syndrome and steroid-resistant pericardial effusion in an SLE patient. 相似文献
15.
Infectious complications in SLE after immunosuppressive therapies 总被引:13,自引:0,他引:13
Immunosuppressive drugs have become the gold standard for the treatment of major organ involvement in systemic lupus erythematosus. The use of immunosuppressive therapy in systemic lupus erythematosus carries significant risks for infection. This article reviews infectious complications in systemic lupus erythematosus, focusing on effects of immunosuppressive therapy. Patients with systemic lupus erythematosus appear to carry an intrinsically increased risk for infection. Recent studies support this notion further by showing increased risk for serious infections in patients with systemic lupus erythematosus who had mannose-binding lectin deficiency associated with homozygous mannose-binding lectin variant alleles. Patients with systemic lupus erythematosus who were homozygous for mannose-binding lectin variant alleles had a fourfold increase in the incidence of infections, requiring hospitalization. In terms of extrinsic risk factors for infection, use of steroids and cyclophosphamide are the strongest risk factors. The effect of these drugs on infection is also dose dependent. The incidence of infectious complications in patients treated with mycophenolate mofetil, a newly used immunosuppressive drug in systemic lupus erythematosus, appears less frequent compared with cyclophosphamide. Herpes zoster is still the most common viral infection in patients with systemic lupus erythematosus treated with cyclophosphamide and mycophenolate mofetil. Overall data indicate that patients with systemic lupus erythematosus may have intrinsically increased risks for infection that are augmented by immunosuppressive therapies. Cyclophosphamide, in particular in combination with high-dose glucocorticoids, has the strongest effect in suppressing the immune responses against microorganisms. Careful monitoring of infectious complications is warranted in patients with systemic lupus erythematosus receiving immunosuppressive therapies, in particular those on high-dose glucocorticoids and cytotoxic drugs. 相似文献
16.
Protein-Losing Enteropathy in Systemic Lupus Erythematosus 总被引:3,自引:0,他引:3
Shojiro Takagi M.D. Kazuo Oshimi M.D. Morito Sumiya M.D. Nobuyuki Gonda M.D. Shogo Kano M.D. Fumimaro Takaku M.D. 《The American journal of gastroenterology》1983,78(3):152-154
Although protein-losing enteropathy can be associated with a variety of disorders, only three cases have been described in association with systemic lupus erythematosus. In the case described herein, protein-losing enteropathy was the only clinical manifestation of systemic lupus erythematosus. Small intestinal biopsy revealed edema and mild mononuclear cell infiltration in lamina propria mucosae and no evidence of lymphangiectasia. X-ray studies of the gastrointestinal tract were normal. Protein-losing enteropathy responded to high-dose corticosteroid therapy. Protein-losing enteropathy should be suspected as a possible cause of unexplained hypoalbuminemia in systemic lupus erythematosus. 相似文献
17.
Kaneko K Matsuda M Sekijima Y Hosoda W Gono T Hoshi K Shimojo H Ikeda S 《Clinical rheumatology》2005,24(2):158-161
This report concerns a patient with systemic lupus erythematosus (SLE) who died of acute respiratory distress syndrome (ARDS) 1 day after the onset of pulmonary symptoms. Autopsy demonstrated severe hemophagocytosis in the bone marrow and histopathology indicating a marked increase in vascular permeability in both lungs and kidneys. In this patient, active SLE and associated hemophagocytic syndrome may have induced an increase in the production of inflammatory cytokines, which immediately induced ARDS. Since fatal ARDS can occur as a life-threatening complication of SLE, careful observation is necessary, particularly when there are clinical findings suggestive of associated hemophagocytic syndrome. 相似文献
18.
Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus 总被引:2,自引:0,他引:2
Hoshi K Matsuda M Ishikawa M Mitsuhashi S Gono T Hashimoto T Ikeda S 《Clinical rheumatology》2004,23(3):252-255
We report a patient with systemic lupus erythematosus (SLE) who developed fulminant pulmonary hemorrhage. This patient also showed liver dysfunction, bicytopenia and hyperferritinemia, with an increase in serum levels of interleukin (IL)-1, IL-6 and tumor necrosis factor- (TNF-) at the onset of pulmonary symptoms, probably indicating an associated hemophagocytic syndrome. Despite an acute progressive course temporarily requiring mechanical ventilation the patient was successfully treated with continuous drip infusion of tacrolimus, plasmapheresis and intravenous high-dose immunoglobulin and corticosteroid. In this patient increased inflammatory cytokines ascribable to activation of macrophages and/or helper T cells were considered to play an important role in the pathogenesis of the pulmonary hemorrhage. Because this complication is frequently fatal in SLE, intensive therapy, including immunosuppressants and plasmapheresis, should be actively considered as early as possible after onset.Abbreviations HPS Hemophagocytic syndrome - SLE Systemic lupus erythematosus - TNF Tumor necrosis factor 相似文献
19.
Kuniyoshi Kamiya Kazuhiro Kurasawa Satoko Arai Reika Maezawa Ryosuke Hanaoka Kotaro Kumano Takeshi Fukuda 《Modern rheumatology / the Japan Rheumatism Association》2010,20(1):81-85
We report the case of a patient with systemic lupus erythematosus (SLE) who first revealed hemophagocytic syndrome (HPS),
which was treated successfully with glucocorticoid and intravenous cyclophosphamide. The patient then demonstrated refractory
thrombotic thrombocytopenic purpura (TTP) with normal a disintegrin and metalloprotease with thrombospondin motifs (ADAMTS)-13
activity that responded well to rituximab. After rituximab treatment, the patient showed a flare of HPS that was controlled
by additional intravenous cyclophosphamide treatment. This case showed that TTP with normal ADAMTS-13 activity is B-cell dependent
and indicated that B-cell depletion might exacerbate some autoimmune conditions in SLE. 相似文献
20.
Antiphospholipid antibody-associated hemophagocytic syndrome] 总被引:1,自引:1,他引:0
Autoimmune diseases such as systemic lupus erythematosus (SLE) are known to be causative disorders of reactive hemophagocytic syndrome (HPS). We recently encountered a case of HPS associated with the presence of antiphospholipid antibodies (aPL). This patient showed severe thrombocytopenia (0.2 x 10(4)/microliter) and moderate anemia (Hb; 7.6 g/dl). Bone marrow smears showed normal cellularity and an increase in mature-looking histiocytes scattered among the hematopoietic cells, which accounted for approximately 3% of all nucleated cells and were distributed unevenly. These cells showed marked phagocytosis of hematopoietic cells, including megakaryocytes, erythroblasts, and a few neutrophils. In this patient, there is no possible causative factor of HPS (such as viral infection, lymphoma, and systemic lupus erythematosus) except the presence of aPL. There have been no previously reported cases describing the relationship between aPL and HPS. This case indicate that attention should be given to the possibility that certain patients with aPL-associated cytopenia may display accompanying intramedullary hemophagocytic phenomena. 相似文献